{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T08:24:33Z","timestamp":1775895873058,"version":"3.50.1"},"reference-count":24,"publisher":"Informa UK Limited","issue":"34","license":[{"start":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T00:00:00Z","timestamp":1632787200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Kite Pharma, A Gilead Company"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.2217\/fon-2021-0160","type":"journal-article","created":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T12:24:30Z","timestamp":1632831870000},"page":"4697-4709","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":8,"title":["CAR T-Cell Therapy in Relapsed\/Refractory Diffuse Large B-Cell Lymphoma: Physician Preferences Trading off Benefits, Risks and Time to Infusion"],"prefix":"10.1080","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7346-2132","authenticated-orcid":false,"given":"Marco","family":"Boeri","sequence":"first","affiliation":[{"name":"RTI Health Solutions,\rBelfast BT2 8LA,\rUK"},{"name":"Queen\u2019s University Belfast,\rBelfast BT7 1NN,\rUK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8587-2873","authenticated-orcid":false,"given":"Anna G","family":"Purdum","sequence":"additional","affiliation":[{"name":"Kite Pharma,A Gilead Company,\rSanta Monica,\rCA 90404,\rUSA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2000-3677","authenticated-orcid":false,"given":"Jessie","family":"Sutphin","sequence":"additional","affiliation":[{"name":"RTI Health Solutions,Research Triangle Park,\rNC 27709,\rUSA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3129-7268","authenticated-orcid":false,"given":"Brett","family":"Hauber","sequence":"additional","affiliation":[{"name":"RTI Health Solutions,Research Triangle Park,\rNC 27709,\rUSA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9357-4227","authenticated-orcid":false,"given":"James A","family":"Kaye","sequence":"additional","affiliation":[{"name":"RTI Health Solutions,\rWaltham,\rMA 02452,\rUSA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2021,9,28]]},"reference":[{"key":"e_1_3_4_3_1","unstructured":"National Cancer Institute (NCI) . Surveillance Epidemiology and End Results Program. Cancer stat facts: non-Hodgkin lymphoma (2021). https:\/\/seer.cancer.gov\/statfacts\/html\/nhl.html"},{"key":"e_1_3_4_4_1","unstructured":"Lymphoma Research Foundation . Diffuse large B-cell lymphoma (2019). www.lymphoma.org\/aboutlymphoma\/nhl\/dlbcl\/"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-577189"},{"key":"e_1_3_4_6_1","unstructured":"National Cancer Institute (NCI) . Surveillance Epidemiology and End Results Program. Cancer stat facts: NHL \u2013 diffuse large B-cell lymphoma (DLBCL) (2021). https:\/\/seer.cancer.gov\/statfacts\/html\/dlbcl.html"},{"key":"e_1_3_4_7_1","unstructured":"Kite: A Gilead Company . Yescarta (axicabtagene ciloleucel) prescribing information (2017). www.yescarta.com\/wp-content\/uploads\/yescarta-pi.pdf"},{"key":"e_1_3_4_8_1","unstructured":"Novartis . Kymriah (tisagenlecleucel) prescribing information (2018). www.novartis.us\/sites\/www.novartis.us\/files\/kymriah.pdf"},{"key":"e_1_3_4_9_1","unstructured":"US FDA . Breyanzi (lisocabtagene maraleucel) prescribing information (2021). www.fda.gov\/media\/145711\/download"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/hec.1697"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-014-0170-x"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-018-0734-2"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2014.10.004"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S125245"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2010.11.013"},{"key":"e_1_3_4_16_1","unstructured":"Kuhfeld W . Marketing research methods in SAS: experimental design choice conjoint and graphical techniques. SAS Institute Inc. NC USA (2010)."},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1177\/002224379403100408"},{"key":"e_1_3_4_18_1","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/1-4020-3684-1_7","volume-title":"Applications of Simulation Methods in Environmental and Resource Eonomics.","author":"Train K","year":"2005","unstructured":"Train K , SonnierG. Mixed logit with bounded distributions of correlated partworths. In: Applications of Simulation Methods in Environmental and Resource Eonomics.ScarpaR, AlberiniA (Eds). Springer Publisher, Dordrecht, The Netherlands, 117\u2013134 (2005)."},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1017\/CBO9780511805271"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1177\/002224379303000303"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2020.06.008"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01397-9"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2020.09.009"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-127490"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-126081"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-6367(21)00096-8"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2021-0160","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:47:28Z","timestamp":1719125248000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2021-0160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,28]]},"references-count":24,"journal-issue":{"issue":"34","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["10.2217\/fon-2021-0160"],"URL":"https:\/\/doi.org\/10.2217\/fon-2021-0160","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,28]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-02-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-02","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}